{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:01:26Z","timestamp":1790949686692,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Idiopathic inflammatory myopathies (IIMs) are characterized by chronic muscle inflammation and often involve multiple organ systems. Despite treatment, a large number of patients still experience relapse or disease progression. Currently, there is a lack of high-quality studies specifically focusing on recurrence, and early identification of patients at high risk of recurrence remains challenging.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included patients with idiopathic inflammatory myopathy complicated by interstitial lung disease who were hospitalized in the First Affiliated Hospital of Ningbo University from January 2018 to December 2024. All included individuals were followed up for at least 12\u202fmonths. The diagnosis of idiopathic inflammatory myopathies and interstitial lung disease (ILD) was based on relevant criteria. A wide range of clinical and laboratory data were collected. Significant variables were screened through univariate and multivariate regression analyses, and risk models for predicting recurrence at 1, 2, and 3\u202fyears were constructed, with subsequent evaluation of the models\u2019 performance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 93 included patients, the recurrence rate was 23.7%, with a median time to recurrence of 38\u202fmonths. Approximately 26.1% of recurrences were attributed to drug discontinuation or adjustment. Multivariate analysis suggested that positive anti-RO52 antibody, positive anti-PL7 antibody, elevated white blood cell count, elevated ALT, and elevated LDH were positively correlated with the risk of recurrence. The area under the ROC curve (AUC) for recurrence prediction was: 1-year: 1.00 (95% CI: 1.00\u20131.00), 2-year: 0.91 (95% CI: 0.75\u20131.08), 3-year: 0.92 (95% CI: 0.78\u20131.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on baseline clinical and laboratory indicators, this study developed a tool with good predictive ability for IIM-ILD recurrence, which can accurately assess individual recurrence risk and assist in early clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>IRB No:2025092RS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1666332","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:17:58Z","timestamp":1757477878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo"],"prefix":"10.3389","volume":"12","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/nejm197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/keaa372","article-title":"Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"9679944","DOI":"10.1155\/2024\/9679944","article-title":"An observational study on the clinical characteristics and prognosis of patients with interstitial lung disease secondary to dermatomyositis and Antisynthetase syndrome","volume":"2024","author":"Lei","year":"2024","journal-title":"Int J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir Investig"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/diagnostics15030275","article-title":"Recognition of idiopathic inflammatory myopathies underlying interstitial lung diseases","volume":"15","author":"Morina","year":"2025","journal-title":"Diagnostics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2169\/internalmedicine.3418-23","article-title":"Tension pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a case report and literature review","volume":"63","author":"Okabayashi","year":"2024","journal-title":"Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.30077","article-title":"Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease","volume":"63","author":"Cottin","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin a to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology (Carlton, Vic)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e29108","DOI":"10.1097\/md.0000000000029108","article-title":"Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: a retrospective analysis","volume":"101","author":"Lian","year":"2022","journal-title":"Medicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08916930600622884","article-title":"Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies","volume":"39","author":"Yoshifuji","year":"2006","journal-title":"Autoimmunity"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/rheumatology\/kev192","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.31138\/mjr.280823.lto","article-title":"Long term outcomes in idiopathic inflammatory myositis: an observational epidemiologic study over 15 years","volume":"34","author":"Janardana","year":"2023","journal-title":"Mediterranean J Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"978708","DOI":"10.3389\/fimmu.2022.978708","article-title":"Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease","volume":"13","author":"Gui","year":"2022","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"908365","DOI":"10.3389\/fmed.2022.908365","article-title":"A new predictive model for the prognosis of MDA5(+) DM-ILD","volume":"9","author":"Niu","year":"2022","journal-title":"Front Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2440621","DOI":"10.1080\/07853890.2024.2440621","article-title":"Severe interstitial lung disease risk prediction in anti-melanoma differentiation-associated protein 5 positive dermatomyositis: the STRAD-Ro52 model","volume":"57","author":"Xiao","year":"2025","journal-title":"Ann Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s003300000648","article-title":"High-resolution CT of diffuse interstitial lung disease: key findings in common disorders","volume":"11","author":"Schaefer-Prokop","year":"2001","journal-title":"Eur Radiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10067-022-06424-4","article-title":"An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome","volume":"42","author":"Chen","year":"2023","journal-title":"Clin Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e002076","DOI":"10.1136\/bmjresp-2023-002076","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"105920","DOI":"10.1016\/j.rmed.2020.105920","article-title":"Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review","volume":"165","author":"Liu","year":"2020","journal-title":"Respir Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1407633","DOI":"10.3389\/fimmu.2024.1407633","article-title":"Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy","volume":"15","author":"Matsuda","year":"2024","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1007\/s10072-020-04911-7","article-title":"The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease","volume":"42","author":"Huang","year":"2021","journal-title":"Neurol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","article-title":"Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases","volume":"55","author":"Fujisawa","year":"2017","journal-title":"Respir Investig"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10067-023-06542-7","article-title":"Elevated platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with polymyositis\/dermatomyositis: a retrospective study","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1007\/s10067-024-07110-3","article-title":"Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study","volume":"43","author":"Tian","year":"2024","journal-title":"Clin Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/crj.13616","article-title":"Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease","volume":"17","author":"Li","year":"2023","journal-title":"Clin Respir J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1628748","DOI":"10.3389\/fimmu.2025.1628748","article-title":"Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13075-020-02286-w","article-title":"AST\/ALT ratio as a predictor of mortality and exacerbations of PM\/DM-ILD in 1\u202fyear-a retrospective cohort study with 522 cases","volume":"22","author":"Li","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/s2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1666332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:17:59Z","timestamp":1757477879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1666332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":42,"alternative-id":["10.3389\/fmed.2025.1666332"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1666332","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1666332"}}